September 26, 2023
Japan approved its first Alzheimer’s disease (AD)-modifying therapy, Leqembi (lecanemab), on September 25. The drug is almost certain to trigger a cost control rule for potential blockbusters, which requires ad-hoc price-setting discussions prior to the actual pricing process, but the...read more